Long Acting Formulations for Treating Hepatitis B

New formulation improves treatment of Hepatitis B

  • Sustained delivery of antiviral agents
  • Decreased dosing
  • Increased patient compliance

Licensing Manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-536-9881


New formulation improves treatment of Hepatitis B

Researchers at the University of Nebraska Medical Center are developing promising new treatment strategies for Hepatitis B.
The innovation features injectable, long acting-slow release prodrug-based formulations of a class of antiviral drugs called thiazolides. The new formulation can be effectively packaged into nanoparticles that slowly release the active drug in a patient’s body.
The goal of this strategy is to create a once-a-month injectable formulation, or even a once every three- or six-month injectable formulation.
Currently, the researchers are developing prodrug formulations of nitazoxanide for testing in animal models of Hepatitis B infection.
They are also developing prodrug formulations of other anti-viral drugs such as nucleoside reverse transcriptase inhibitors, which can also treats Hepatitis B.
To discuss licensing opportunities contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-536-9881.

Additional Info

Intellectual Property

  • U.S. patent application has been filed